Abstract:4148 Apoptosis, or programmed cell death, plays a key role in normal tissue homeostasis ensuring a proper balance between cell production and cell loss. Anti-apoptotic Bcl-2-family proteins are key regulators of the apoptotic pathway and their increased expression in human malignancies is associated with disease progression, tumor resistance to chemotherapy, radiation and poor clinical outcome. Recently,a novel Bcl-2/Bcl-xL/Bcl-w inhibitor (ABT-737) has been developed, which is highly potent in killing tumor cells displayinghigh levels of Bcl-2 and dependent upon Bcl-2 forsurvival. However, ABT-737 exhibits a relatively low affinityfor Mcl-1 and is considerably less efficient in killing tumor cellsexpressing high Mcl-1 levels. Several groups provide strong evidence that Mcl-1 is the major factor that causes resistance to ABT-737 in cancer cells derived from diverse solid tumors, and one approach for overcoming this resistance could be the combination of ABT-737 with agentscapable of down-regulating/inhibiting Mcl-1. Here, we describe a high throughput screening approach that led to the identification of several chemical classes, small molecule Mcl-1 inhibitors. The compounds were characterized in a number of assays including in vitro binding using fluorescence polarization based assay, SPR solution competitive assay, heteronuclear single quantum correlation (HSQC) NMR spectroscopy, pull-down assay, functional assay for cytochrome c and Smac release and a cell-based viability assay with human cancer cells. The most potent of the inhibitors identified was compound 65, which binds to Mcl-1 protein with IC50 of 0.3 μM, showing >100-fold selectivity over Bcl-xL and 60-fold selectivity over Bcl-2 protein. 15N HSQC spectra conclusively showed that compound 65 interacts with the BH3 domain in Mcl-1 protein and many residues in the BH3 binding groove of Mcl-1 protein were affected by 65. Furthermore, pull-down assay demonstrates that the compound 65 is able in dose dependent manner to disrupt interactions between endogenous Mcl-1 protein and biotin labeled Noxa and Bid BH3 peptides, but not between Bid BH3 peptide and other members of Bcl-2 family (Bcl-xL and Bcl-2). Functional studies showed that compound 65 effectively antagonizes recombinant Mcl-1 protein and promotes release of cytochrome c and Smac from isolated mitochondria. Compound 65 displayed cytotoxicity with IC50 from 3 μM to 8 μM against a number of human cancer cell lines with high level of Mcl-1 protein. Collectively, these data indicate that 65 represents a novel and bone fide small-molecule inhibitor of Mcl-1 and a promising lead compound for further optimization toward developing a new class of anticancer drugs by targeting the Mcl-1 protein.

Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells

Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cells

Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells

BAY61-3606 Potentiates the Anti-Tumor Effects of TRAIL Against Colon Cancer Through Up-Regulating DR4 and Down-Regulating NF-κB.

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Reduction of TRAIL-Induced Mcl-1 and Ciap2 by C-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death

The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo

Discovery and Characterization of New Small-Molecule Inhibitors of Mcl-1 by High-Throughput Screening

GDC-0941 Sensitizes Breast Cancer to ABT-737 in Vitro and in Vivo Through Promoting the Degradation of Mcl-1.

The PI3 Kinase Inhibitor NVP-BKM120 Induces GSK3/FBXW7-dependent Mcl-1 Degradation, Contributing to Induction of Apoptosis and Enhancement of TRAIL-induced Apoptosis

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells

Bufadienolide Compounds Sensitize Human Breast Cancer Cells to TRAIL-induced Apoptosis Via Inhibition of STAT3/Mcl-1 Pathway

Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors

Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP

Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA

Small molecule Mcl-1 inhibitor for triple negative breast cancer therapy

Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer